Regeneron Pharmaceuticals, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Regeneron Pharmaceuticals, Inc. (REGN) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Regeneron Pharmaceuticals, Inc. clearly outscores UnitedHealth Group Incorporated on Q·Score (8.5 vs 6.1 out of 10), led by Health (9.7 vs 5.3) and Quality (8.8 vs 5.9). UnitedHealth Group Incorporated scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for REGN (+36.1%) than for UNH (-0.3%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.1× debt-to-equity).
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
Fundamentals
Frequently Asked Questions
REGN vs UNH: which stock scores better overall?
Based on Q·Score, Regeneron Pharmaceuticals, Inc. (REGN) scores 8.5/10 versus UnitedHealth Group Incorporated (UNH) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: REGN or UNH?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Growth (7.3/10 vs 5.1/10). Regeneron Pharmaceuticals, Inc. reports revenue growth (19.0% YoY) while UnitedHealth Group Incorporated reports (2.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is REGN or UNH more attractively valued?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Valuation (8.7/10 vs 6.5/10). REGN trades at 11.4× P/E versus UNH at 19.5×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about REGN vs UNH?
There are 28 analysts covering REGN with a consensus price target of $833.31, and 26 analysts covering UNH with a consensus target of $407.38. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: REGN or UNH?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Quality (8.8/10 vs 5.9/10). Net profit margin: REGN at 29.6%, UNH at 2.7%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: REGN or UNH?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Financial Health (9.7/10 vs 5.3/10). Market beta: REGN at 0.24, UNH at 0.65. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of REGN and UNH?
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalisation of $64.2B, while UnitedHealth Group Incorporated (UNH) has a market cap of $371.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do REGN or UNH pay dividends?
REGN pays a dividend yield of 0.61%, while UNH pays a dividend yield of 2.27%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →